Skip to main content
Retour
RGEN logo

Repligen Corporation

Qualité des données : 100%
RGEN
NASDAQ Healthcare Medical - Instruments & Supplies
116,30 €
▼ 0,05 € (-0,04%)
Cap. Boursière : 6,55B
Fourchette du Jour
113,66 € 117,74 €
Fourchette 52 Semaines
102,97 € 175,77 €
Volume
403 004
Moyenne 50J / 200J
140,91 € / 138,89 €
Clôture Précédente
116,35 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 134,0 0,3
P/B 3,1 2,9
ROE % 2,4 3,7
Net Margin % 6,6 3,8
Rev Growth 5Y % 2,4 10,0
D/E 0,3 0,2

Objectif de Cours des Analystes

Hold
177,50 € +52.6%
Low: 150,00 € High: 200,00 €
P/E Prévisionnel
58,5
BPA Prévisionnel
1,99 €
Croissance BPA (est.)
+0,0%
CA Est.
830 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 5,69 €
5,54 € – 5,79 €
1,5 B 1
FY2029 4,49 €
4,37 € – 4,56 €
1,3 B 1
FY2028 3,30 €
2,64 € – 3,79 €
1,1 B 5

Points Clés

Revenue grew 2,43% annually over 5 years — modest growth
ROE of 2,40% is below average
Debt/Equity of 0,33 — conservative balance sheet
Generating 93,90M in free cash flow
P/E of 133,99 — premium valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 13,93%

Croissance

Revenue Growth (5Y)
2,43%
Revenue (1Y)16,36%
Earnings (1Y)N/A
FCF Growth (3Y)11,94%

Qualité

Return on Equity
2,40%
ROIC1,60%
Net Margin6,62%
Op. Margin8,07%

Sécurité

Debt / Equity
0,33
Current Ratio8,37
Interest Coverage2,57

Valorisation

P/E Ratio
133,99
P/B Ratio3,11
EV/EBITDA112,04
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 16,36% Revenue Growth (3Y) 8,05%
Earnings Growth (1Y) N/A Earnings Growth (3Y) 17,20%
Revenue Growth (5Y) 2,43% Earnings Growth (5Y) -21,43%
Profitability
Revenue (TTM) 738,26M Net Income (TTM) 48,89M
ROE 2,40% ROA 1,66%
Gross Margin 47,09% Operating Margin 8,07%
Net Margin 6,62% Free Cash Flow (TTM) 93,90M
ROIC 1,60% FCF Growth (3Y) 11,94%
Safety
Debt / Equity 0,33 Current Ratio 8,37
Interest Coverage 2,57 Dividend Yield 0,00%
Valuation
P/E Ratio 133,99 P/B Ratio 3,11
P/S Ratio 8,87 PEG Ratio -0,65
EV/EBITDA 112,04 Dividend Yield 0,00%
Market Cap 6,55B Enterprise Value 6,68B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 738,26M 634,44M 632,36M 801,54M 670,53M
Net Income 48,89M -25,51M 35,60M 185,96M 128,29M
EPS (Diluted) 0,86 -0,46 0,63 3,24 2,24
Gross Profit 347,62M 274,65M 278,44M 455,71M 391,25M
Operating Income 59,58M -35,11M 47,70M 224,67M 167,25M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2,95B 2,83B 2,83B 2,53B 2,36B
Total Liabilities 843,57M 856,95M 866,34M 620,90M 608,29M
Shareholders' Equity 2,11B 1,97B 1,96B 1,91B 1,75B
Total Debt 689,95M 686,25M 711,80M 422,96M 366,05M
Cash & Equivalents 566,02M 757,36M 751,32M 523,46M 603,81M
Current Assets 1,14B 1,07B 1,11B 998,12M 931,68M
Current Liabilities 135,83M 126,79M 164,94M 404,20M 375,26M